Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
about
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine DevelopmentContribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in miceRegulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission.Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA VirusesDNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titersEnhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge.Targeting plasmid-encoded proteins to the antigen presentation pathways.Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.DNA vaccines: a rational design against parasitic diseases.Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain.DNA Immunization for HIV Vaccine Development.Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.Signal peptide replacements enhance expression and secretion of hepatitis C virus envelope glycoproteins.Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice.Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.DNA Vaccines Against Maedi-Visna Virus.Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tPA signal sequence.
P2860
Q27472925-7B4FECB1-C3CC-4218-AA74-DEDE0B3C7283Q27477561-52802F7E-0C77-4799-8EF0-3A93A3C6E961Q33717736-3C8D983E-1FE3-4B24-9E8F-DD766FFC1BA1Q33763297-B0A661DE-226F-447D-A481-0A5A03C387C1Q33854615-D5ECD040-9806-46BD-B1C1-22EF9A52C278Q34599516-0C885051-425D-41BC-B885-BC14B7C661AEQ34806497-AA9ED414-61B7-497D-ADD9-9A7DD2629BC7Q35640984-C5AB3F52-6833-4CF0-937D-2D5698008B57Q35796747-FFB74D35-5740-4647-BF29-64D618EA4E4FQ35826370-CF701303-BC8D-4E28-A59A-6E55AA69F74EQ36010016-E84D26F0-2A49-4A43-8A63-5C1145C513C8Q36144935-6230D945-6A03-4F31-AEB5-0685F6FF6F9AQ37398200-07B3685B-7AF7-4378-B161-54FC0B3CCFCCQ37530471-22965C3C-1F5E-4117-AAD2-4C2AE795476CQ37547365-024102A1-B294-4E2C-B3C3-A496D7AD20E9Q37682900-EBCFA58F-90B8-48E1-93B2-5E69EF2922D5Q37683010-F27A765F-3090-4D3E-9F80-5A9281D4A99AQ38581981-E4C96E96-4AEF-402A-B4D1-067793A0456CQ39320921-25258013-32AA-49DF-865B-E5BB09A9017EQ39613193-0DDDFE6E-4153-4497-9E05-0A56F940F346Q40299563-92F93096-CC13-42A1-BA7C-B059370C6BC7Q40471278-F08F1503-61DC-4C1D-A775-3652AF3DF729Q40715606-D4A5780B-6ACF-4104-9D2E-9094721F2095Q41148377-284EB7AE-1069-4D7D-93C3-3230B7A94740Q42800282-1790DA43-6137-4D1C-9D3B-897B7EF14CFEQ51009640-4C5EEBBE-C601-4F2E-9E98-FBA7C663EFFD
P2860
Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Enhancement of primary and sec ...... igen to the secretory pathway.
@ast
Enhancement of primary and sec ...... igen to the secretory pathway.
@en
type
label
Enhancement of primary and sec ...... igen to the secretory pathway.
@ast
Enhancement of primary and sec ...... igen to the secretory pathway.
@en
prefLabel
Enhancement of primary and sec ...... igen to the secretory pathway.
@ast
Enhancement of primary and sec ...... igen to the secretory pathway.
@en
P2093
P2860
P1433
P1476
Enhancement of primary and sec ...... igen to the secretory pathway.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.13.5997-6005.2000
P577
2000-07-01T00:00:00Z